Bold truth: NZ’s health system pays for symptoms, not prevention, and that choice costs lives and money. This rewrite keeps the core message intact while slightly expanding context to help beginners understand why primary care matters and how funding shapes outcomes.
Primary care prevents health problems from spiraling into expensive crises—and yet New Zealand funds it in a way that often undermines its own purpose.
Think about a typical pharmacy visit. It looks like a simple exchange: you hand over a prescription and walk away with pills. But behind that box lies a great deal of clinical judgment: a pharmacist spotting a dangerous drug interaction, or a general practitioner untangling several conditions before deciding what to prescribe. This invisible work is exactly what stops disasters and keeps people out of hospital. The problem is that NZ’s funding model barely recognizes or rewards this essential clinical effort.
Instead, the system relies on a hidden subsidy embedded in dispensing fees and retail margins. That structure actively penalizes the very time and expertise needed for high-quality care, especially for patients with complex health needs.
This is where New Zealand’s primary care model starts to fail: not because clinicians lack skill, but because the way we pay for their time discourages the kind of care that prevents harm. Fixing this structural flaw is urgent.
When prevention goes unpaid
Just as pharmacists prevent harm through careful medication reviews, GPs prevent deterioration through time-intensive consultations with patients who have complex needs.
Spending 30 minutes with a family doctor can be the difference between stability and a hospital admission. When it works, there is no adverse drug reaction and no trip to the emergency department.
Research consistently links primary care continuity to fewer hospitalisations. Yet our funding structures don’t reward the absence of harm; they reward quantity over-quality.
New Zealand’s primary care system operates on a model where the intensive care required by the sickest patients is financially supported by high-volume, transactional care aimed at healthier ones.
No one explicitly pays for the time a pharmacist spends on the phone to challenge a risky dosage. That life-saving action is covered by the margin on dispensing many routine scripts, or by the profit from selling vitamins and sunscreen at the front of the shop.
In effect, the profits from simple transactions quietly bankroll the complex care. This isn’t an accident; it’s a built-in feature of the Community Pharmacy Services Agreement.
For GPs, capitation funding models often fail to reflect the true variation in patient complexity.
A practice in a deprived community serving people with diabetes, chronic lung disease, or depression often receives roughly the same base funding as a clinic doing routine check-ups in a wealthier area.
The clinics doing the hardest work are financially penalised for it. Underpaying for clinical time contributes to burnout among doctors, nurses, and pharmacists and leaves high-need communities with less care than they require.
Why price caps don’t work
When budgets are tight, governments trim fees and margins. But illness persists, and the pressure simply shifts to other, more expensive parts of the system.
If a pharmacy must push up dispensing volume to stay solvent, pharmacists have less time for crucial safety checks. If a GP clinic is squeezed, consultation times shrink and some clinicians stop taking new patients. Complex needs go unaddressed.
That unmet need often accumulates as latent demand. The patient who misses a thorough medication review may later show up at the emergency department with a severe adverse reaction or a flare of a chronic condition.
By then, the patient is much sicker, and the cost to the taxpayer is far higher than the primary care intervention would have been. Underpaying for time in primary care is a costly false economy.
Fixing the flaws
The hidden subsidy must be addressed by shifting from volume-based funding to complexity-based funding.
A pharmacist performing a comprehensive medication reconciliation for an elderly patient on ten medications should be paid for that clinical help, even if no product is dispensed. That professional judgment has value in its own right.
The same logic applies to general practice. A consultation that prevents a hospital admission requires far more time and skill than a routine script renewal.
Funding models must recognize patient variation and adequately support practices serving high-need populations, so clinicians can spend more time with complex patients, not less.
When a primary care professional identifies a prescribing error or intervenes to stop a chain of avoidable harm, the hospital system saves thousands of dollars. That saving should be explicitly recognised and remunerated.
New Zealand cannot keep relying on retail margins and the goodwill of overworked clinicians to prop up its primary care sector. If it does, the safety net will continue to fray, and preventable harm will eventually follow.
Note: Dylan A Mordaunt is a Research Fellow at Te Herenga Waka - Victoria University of Wellington, Flinders University, and The University of Melbourne. This piece originally appeared in The Conversation and reflects the author’s analysis on how primary care prevention intersects with funding structures.
Would you like this rewritten version tailored for a specific audience (patients, policymakers, clinicians) or with a sharper focus on particular examples (pharmacist safety reviews, GP time management, or community health)? If so, tell me the target readers and the tone you prefer (more formal, more accessible, or more opinionated).
